Abstract
Introduction Left atrial appendage occlusion (LAAO) has emerged as an alternative to direct oral anticoagulants (DOACs) for stroke prevention in atrial fibrillation (AF), particularly in patients with contraindications to long-term anticoagulation. However, comparative efficacy and safety remain uncertain.
Methods We conducted a systematic review and meta-analysis of studies published up to September 2025. A total of 395 studies were screened, and 14 met eligibility criteria, encompassing 683,659 patients. Data on baseline demographics, thromboembolic outcomes, bleeding complications, and mortality were extracted. Pooled estimates were calculated using random-effects models in Stata 18.0. Risk of bias was assessed with ROBINS-I and RoB 2.0, and certainty of evidence was graded using GRADE.
Results Of the total population, 14,931 patients underwent LAAO and 640,888 received DOACs. The cohort included 287,031 males and 339,818 females, with hypertension present in 8262 LAAO and 189,627 DOAC patients, CKD in 4256 vs 122,521, and diabetes in 7422 vs 284,861, respectively. LAAO patients had a mean CHA DS -VASc score of 4.58 compared to 4.92 in DOAC patients. Meta-analysis showed no significant differences between LAAO and DOACs in all-cause mortality (RR 0.08; 95% CI –0.77 to 0.92), cardiovascular mortality (RR 0.67; 95% CI –0.60 to 1.94), thromboembolic events (RR 0.47; 95% CI –0.83 to 1.77), or major bleeding (RR 0.58; 95% CI –0.71 to 1.87).
Conclusion LAAO provides stroke prevention comparable to DOACs without significant differences in mortality or bleeding. LAAO may represent an appropriate option in AF patients with high bleeding risk or contraindications to anticoagulation. Further randomized trials are warranted to refine patient selection and confirm long-term outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Protocols
https://www.crd.york.ac.uk/PROSPERO/view/CRD420251152538
Funding Statement
none
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
supplementary file
